Would / could we change strategy and go generic? - I'm not convinced and the key remains in the fact that we are already competing with generics and must have a strategy to deal with it and the impending expirys anyway.
The @mita slide yesterday about the extent and growth in generics was probably the most telling (at 310316 grew rapidly to 20% market share, although growth in last 6 months much slower). So ACR need to factor in a reduction in sales revenue going forward, say about 80% going forward.
The question is how much of PAT will be distributed? - I'd say 60% - so 9E * 60% = say 5c
Re the action costs, ACR said somewhere there was no cost to ACR and the CFO confirmed this on the phone the other day, I assume Lilly also confirmed the same for the appeal?
Ann: Acrux and Eli Lilly to appeal patent ruling on Axiron-ACR.AX, page-24
-
- There are more pages in this discussion • 5 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
